X4 slips after mid-stage data for lead drug in neutropenia

seekingalpha06-28

X4 Pharmaceuticals (NASDAQ:XFOR) traded sharply lower on Thursday after the biotech updated data from an ongoing Phase 2 trial for its lead candidate mavorixafor in chronic neutropenia (CN), a rare ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2446562763?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1028830260/image_1028830260.jpg","is_english":true,"pubTime":"2024-06-28 01:40","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2446562763","market":"hk","top_or_hot":-1,"title":"X4 slips after mid-stage data for lead drug in neutropenia","media":"seekingalpha","content":"<div>\n<p>X4 Pharmaceuticals (NASDAQ:XFOR) traded sharply lower on Thursday after the biotech updated data from an ongoing Phase 2 trial for its lead candidate mavorixafor in chronic neutropenia (CN), a rare ...</p>\n\n<a href=\"https://seekingalpha.com/news/4120247-x4-stock-slips-after-trial-data-lead-drug\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>X4 slips after mid-stage data for lead drug in neutropenia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nX4 slips after mid-stage data for lead drug in neutropenia\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-28 01:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4120247-x4-stock-slips-after-trial-data-lead-drug><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>X4 Pharmaceuticals (NASDAQ:XFOR) traded sharply lower on Thursday after the biotech updated data from an ongoing Phase 2 trial for its lead candidate mavorixafor in chronic neutropenia (CN), a rare ...</p>\n\n<a href=\"https://seekingalpha.com/news/4120247-x4-stock-slips-after-trial-data-lead-drug\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://seekingalpha.com/news/4120247-x4-stock-slips-after-trial-data-lead-drug","article_id":"2446562763","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1028830260/image_1028830260.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2446562763","pubTimestamp":1719510016,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"X4 Pharmaceuticals  traded sharply lower on Thursday after the biotech updated data from an ongoing Phase 2 trial for its lead candidate mavorixafor in chronic neutropenia , a rare blood disorder. Citing a May 24 data cut, the Boston, Massachusetts-based biotech said mavorixafor, which X4  markets as Xolremdi for an ultra-rare disorder called WHIM syndrome, demonstrated a safety profile consistent with its previous clinical studies. However, three out of 23 subjects who received the drug discontinued the therapy due to non-serious adverse events. CN is characterized by a low number of white blood cells known as neutrophils, which leads to a higher incidence of infections. As for efficacy, the company said that once-daily oral mavorixafor as a single agent with or without granulocyte colony-stimulating factor , the current FDA-approved CN therapy, caused an increase in patients' neutrophil counts at months three and six. The conclusion was based on six subjects who had completed the six","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","XFOR":"X4制药","CN":"Xtrackers MSCI All China Equity ETF"},"translate_title":"中性粒细胞减少症主要药物的中期数据后X4下滑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CN":1,"XFOR":1},"content_text":"X4 Pharmaceuticals (NASDAQ:XFOR) traded sharply lower on Thursday after the biotech updated data from an ongoing Phase 2 trial for its lead candidate mavorixafor in chronic neutropenia (CN), a rare blood disorder. Citing a May 24 data cut, the Boston, Massachusetts-based biotech said mavorixafor, which X4 (XFOR) markets as Xolremdi for an ultra-rare disorder called WHIM syndrome, demonstrated a safety profile consistent with its previous clinical studies. However, three out of 23 subjects who received the drug discontinued the therapy due to non-serious adverse events. CN is characterized by a low number of white blood cells known as neutrophils, which leads to a higher incidence of infections. As for efficacy, the company said that once-daily oral mavorixafor as a single agent with or without granulocyte colony-stimulating factor (G-CSF), the current FDA-approved CN therapy, caused an increase in patients' neutrophil counts at months three and six. The conclusion was based on six subjects who had completed the six-month open-label clinical trial. More data from the study is expected later this year.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2446562763"}